Inteligencia artificial y psicología

Fil: Demaría, Mariela. Universidad Nacional de Córdoba. Facultad de Psicología; Argentina.Fil: Cusmai, Sergio. Aipha G.; ArgentinaFil: Pérez Casas, Alen. Universidad de la República; Uruguay.Fil: Martins, Sabrina. Burger King Argentina; Argentina.Fil: Cavasotto, Mateo. Emi Labs; Argentina.Este encuentro tuvo por objetivo reunir disertantes de diferentes ámbitos donde la Inteligencia Artificial se aplica y su mirada sobre el aporte de la Psicología. Se han mencionado los desafíos que plantea al ser humano el uso de la Inteligencia Artificial en la vida cotidiana y en el futuro del trabajo, en el desarrollo de las profesiones. Se destaca el rol de la psicología como un factor relevante para aplicar tecnología que solucione y mejore el rendimiento en las organizaciones, a través de la eficiente utilización del tiempo y de los recursos tecnológicos como aplicaciones, predictores de comportamiento, etc. Se coincide en que la tecnología no reemplaza al ser humano, sino que lo puede potenciar, a través de el desarrollo de nuevas Realidades. Otro tema a considerar es la protección de datos, el conocimiento informado, el cruzamiento de datos y su uso justo, los datos abiertos, ciencia abierta y software libre, como garantías mínimas. Y la necesidad de construir ciudadanía digital y la necesidad de trabajar en una ética en relación a los desarrollos tecnológicos y de observar a la tecnología como aliada del desarrollo humano.Fil: Demaría, Mariela. Universidad Nacional de Córdoba. Facultad de Psicología; Argentina.Fil: Cusmai, Sergio. Aipha G.; ArgentinaFil: Pérez Casas, Alen. Universidad de la República; Uruguay.Fil: Martins, Sabrina. Burger King Argentina; Argentina.Fil: Cavasotto, Mateo. Emi Labs; Argentina

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

This is a retrospective analysis on the safety and activity of compassionate Ipilimumab and Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as a first-line regimen. IPI was infused at 1 mg/kg in combination with Nivolumab 3 mg/kg every three weeks for four doses, followed by maintenance Nivolumab (240 or 480 mg flat dose every two or four weeks, respectively) until disease progression or unacceptable toxicity. A total of 324 patients started IPI-NIVO at 86 Italian centers. Median age was 62 years, 68.2% IMDC intermediate risk. Primary tumor had been removed in 65.1% of patients. Two hundred and twenty patients (67.9%) completed the four IPI-NIVO doses. Investigator-assessed overall response rate was 37.6% (2.8% complete). Twelve-month survival rate was 66.8%, median progression-free survival was 8.3 months. Grade 3 or 4 treatment-related adverse events occurred in 67 patients (26.9%). IMDC intermediate risk, nephrectomy, BMI ≥ 25 kg/m2, and steroid use for toxicities correlated with improved survival, while age < 70 years did not. IPI-NIVO combination is a feasible and effective regimen for the first-line treatment of intermediate-poor IMDC risk mRCC patients in routine clinical practice

Long-term follow-up in children with benign convulsions associated with gastroenteritis

Background: The outcome of benign convulsions associated with gastroenteritis (CwG) has generally been reported as being excellent. However, these data need to be confirmed in studies with longer follow-up evaluations. Aim: To assess the long-term neurological outcome of a large sample of children presenting with CwG. Methods: We reviewed clinical features of 81 subjects presenting with CwG (1994–2010) from three different Italian centers with a follow-up period of at least 3 years. Results: Follow-up period ranged from 39 months to 15 years (mean 9.8 years). Neurological examination and cognitive level at the last evaluation were normal in all the patients. A mild attention deficit was detected in three cases (3.7%). Fourteen children (17.3%) received chronic anti-epileptic therapy. Interictal EEG abnormalities detected at onset in 20 patients (24.7%) reverted to normal. Transient EEG epileptiform abnormalities were detected in other three cases (3.7%), and a transient photosensitivity in one (1.2%). No recurrence of CwG was observed. Three patients (3.7%) presented with a febrile seizure and two (2.5%) with an unprovoked seizure, but none developed epilepsy. Conclusions: The long-term evaluation of children with CwG confirms the excellent prognosis of this condition, with normal psychomotor development and low risk of relapse and of subsequent epilepsy